NF-κB and CREB Are Required for Angiotensin II Type 1 Receptor Upregulation in Neurons

Karla K. V. Haack, Amit K. Mitra, Irving H. Zucker*

Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, United States of America

Abstract

Nuclear factor kappa B (NF-κB) and the Ets like gene-1 (Elk-1) are two transcription factors that have been previously established to contribute to the Angiotensin II mediated upregulation of Angiotensin II type 1 receptor (AT1R) in neurons. The cAMP response element binding protein (CREB) is another transcription factor that has also been implicated in AT1R gene transcription. The goal of the current study was to determine if NF-κB and CREB association was required for AT1R upregulation. We hypothesized that the transcription of the AT1R gene occurs via an orchestration of transcription factor interactions including NF-κB, CREB, and Elk-1. The synergistic role of CREB and NF-κB in promoting AT1R gene expression was determined using siRNA-mediated silencing of CREB. Electrophoretic Mobility Shift Assay studies employing CREB and NF-κB demonstrated increased protein – DNA binding as a result of Ang II stimulation which was blunted by siRNA silencing of CREB. Upstream inhibition of p38 mitogen activated protein kinase (p38 MAPK) with SB203580 or inhibition of the calmodulin kinase (CAMK) pathway using KN-62 blunted changes in CREB and NF-κB expression. These findings suggest that Ang II may activate multiple signaling pathways involving p38 MAPK leading to the activation of NF-κB and CREB, which feed back to upregulate the AT1R gene. This study provides insight into the molecular mechanisms involving multiple transcription factor activation in a coordinated fashion which may be partially responsible for sympathoexcitation in clinical conditions associated with increased activation of the renin angiotensin system.

Introduction

It is well known that the renin-angiotensin system (RAS) plays a central role in mediating the increased sympathetic outflow observed in cardiovascular diseases such as hypertension and heart failure [1]. High levels of circulating Angiotensin II (Ang II) together with increased upregulation of the Angiotensin II type 1 receptor (AT1R) in cardiovascular regulatory regions of the brain such as the rostral ventrolateral medulla (RVLM) contribute to this sympathoexcitation [2,3]. Ang II is known to activate numerous nuclear transcription factors such as nuclear factor kappa B (NF-κB) [4], activator protein 1 (AP-1) [5], and Ets-like protein 1 (Elk-1) [6]. We have shown previously that NF-κB and Elk-1 are two of the key players required for the transcription of AT1R in a CATH.a neuronal cell line [7]. In vivo studies from our laboratory have also shown that in a rat model of chronic heart failure, central AT1R upregulation was dependent on the transcription factors c-Fos and c-Jun, two components of AP-1 [8]. Taken together, these data suggest a cascade of transcription factors that constitute a positive feedback system for the upregulation of AT1R.

Angiotensin II stimulation has also been shown to phosphorylate the cAMP-response element binding protein (CREB) via activation of the p38 MAPK pathway in hypertension [9,10,11,12]. Other signaling cascades that lead to the phosphorylation of CREB include the calcium/Calmodulin kinase (CAMK) pathway [13], extracellular signal regulated protein kinase (ERK) activation [14], protein kinase A [15], and the p38 mitogen activated protein kinase (p38MAPK) pathway [16]. Phosphorylation at Serine 133 results in recruitment of a transcriptional co-activator, CREB-binding protein (CBP), which is essential for transcriptional activation [17]. Studies in neurons have demonstrated the presence of CREB in a functional and regulatory role especially in the mitochondria [18,19].

Increasing evidence suggests that CREB and NF-κB work synergistically to recruit CBP, thereby leading to transcription of multiple genes [20]. The CREB promoter contains binding sites for CREB in close proximity to NF-κB motifs and NF-κB has been shown to interact with other members of the CREB family including c-Fos and c-Jun [21,22]. Co-immunoprecipitation studies have also demonstrated that NF-κB does not directly interact with CREB; instead, CBP serves as a scaffold in NF-κB and CREB in stimulating transcription from the NF-κB promoter [23].

In the current study we tested the hypothesis that in catecholaminergic CATH.a neurons, the upregulation of AT1R gene transcription in response to Ang II is initiated by CREB/NF-κB activation and propagated by downstream transcription factors Elk-1 and c-Fos (a component of AP-1 known to contribute to AT1R upregulation).

Materials and Methods

Cell Culture

The locus coeruleus-like cell line CATH.a neurons (American Type Culture Collection, Manassas, VA) were cultured as
described previously [7]. Briefly, the cells were grown in RPMI 1640 media containing fetal bovine serum (4%), horse serum (5%) and penicillin (100 IU/l) at 37°C and 5% CO2. Cells were seeded on 100 mm petri dishes (1 x 10^5 cells) or 6-well plates (1.5 x 10^5 well). Experiments were performed at 70%–80% confluence and the cells were differentiated in serum-free media for 48–72 hours. Cells were treated with Ang II (Sigma-Aldrich, St. Louis, MO) over specified time periods following which they were harvested and used for further investigation. For each time point beyond 8 hrs, cells were spiked with an additional dose of Ang II at 8 hours and at 16 hours (if applicable). The following inhibitors were used to determine the specific upstream molecular pathways: SB203580 (p38MAPK), KN-62 (Ca2+/calmodulin-dependent protein kinase II), losartan (AT1R) (Sigma-Aldrich), PD98059 (ERK) (Cell Signaling Technology, Danvers, MA).

### Western Blot Analysis

Cells were washed in PBS and lysed with RIPA buffer containing 1% (v/v) Nonidet P40, 0.5% SDS and protease inhibitor cocktail containing 10 µg/ml PMSF, 2 µg/ml leupeptin, 2 µg/ml pepstatin A and 2 µg/ml aprotinin. Cells were disrupted by intermittent sonication. After centrifugation, the amount of protein in the supernatant was measured by a bicinchoninic acid (BCA) protein kit (Pierce, Rockford, IL) using BSA as a standard. Cell lysates were then subjected to SDS/PAGE followed by Western blotting as described previously [24]. Primary antibodies used were p65, CREB, CBP, GAPDH (Santa Cruz Biotechnology Inc., Santa Cruz, CA) and p-CREB (Cell Signaling Technology Inc., Danvers, MA) at a dilution of 1:500–1:1000. Antigen–antibody complexes were detected with HRP (horseradish peroxidase)-linked appropriate secondary antibodies with a Supersignal West Pico Chemiluminescent Detection kit (Pierce, Rockford, IL) and images were digitized and analyzed by UVP BioImaging System (UVP, Upland, CA).

### RT-PCR

Following specific treatment and time course, total RNA was isolated from the neurons using the RNaseasy (Qiagen, Inc. Valencia, CA) RNA isolation kit as per manufacturer’s guidelines. RT-PCR was carried out using 1 µg of total RNA. The purity of the RNA used had a 260/280 ratio of 1.8–2.0. PCR was carried out in a thermocycler (PTC-100, BioRad Hercules, CA) with the following oligonucleotide primers:

- **CREB**: Forward 3’ TACAGGGCCTGCAGACATTAACCA 5’.
- Reverse 5’ ATTCTCTTGTGCTCCCTCGTTCT 3’.
- **GAPDH**: Forward 3’ TGATGCTGGTGCTGAG-5’.
- Reverse 5’ TTGTCATTGAGAGCAATGCCAGGC 3’.

cDNA synthesis was performed using iSCRIPT (BioRad, Hercules, CA) kit using the following parameters: 5 min at 25°C, 30 min at 42°C, 5 min at 85°C. PCR Mastermix (Promega, Madison, WI) was used as per the manufacturer’s guidelines using the specific primer pairs shown above. The reaction was carried out using the following parameters: 95°C for 5 cycles, 95°C for 30 seconds, 65°C for 30 seconds, 72°C for 1 minute, steps 2, 3 and 4 were repeated for 25–30 cycles followed by 10 minute incubation at 72°C and held at 4°C till gel electrophoresis on an agarose gel (1.5%) and visualized by ethidium bromide staining. The bands were analyzed using UVP Bio-imaging Systems – Biochemi 500(Upland, CA). GAPDH was used for normalization.

### Cytoplasmic-nuclear Fractionation

This was done using NE-PER kit (Pierce, Rockford, IL) as per the manufacturer’s instruction. Briefly the cells (10^6/ ml) were resuspended in CER I lysis buffer and vortexed for 15 seconds followed by incubation on ice. CER II buffer was added (5.5% volume) and further vortexed to ensure complete mixing and lysis of cells. The cell suspension was centrifuged and the supernatant yielded the cytoplasmic fraction. To the remaining nuclear pellet NER I buffer was added (50% OF CER I volume) and further vortexed for nuclear membrane lysis. The suspension was centrifuged and the supernatant collected as the nuclear fraction. Total protein in both fractions was determined by BCA assay, and equivalent proteins were loaded. GAPDH was used as a control for normalizing total protein (data not shown).

### Dual Luciferase Reporter Assay

Gigial Reporter assay (SABiosciences, Frederick, MD) was performed as per the manufacturer’s instructions. Briefly, one day before transfection, the cells were plated in 24-well plates in 500 ul of growth medium without antibiotics, so they reached 80–90% confluence at the time of transfection. On the day of transfection, transcription factor responsive reporters for NF-kB and CREB, negative and positive control constructs were diluted in Opti-MEM (Invitrogen, Grand Island, NY) medium without serum and antibiotics. The diluted reporter constructs and the Lipofectamine were then mixed together and allowed to stand at room temperature for 20 minutes for the formation of the DNA-Lipofectamine complex and appropriate volumes were added to each well. Positive and negative controls were run on a separate plate. The cells were then incubated at 37°C for 24 hours, following which they were subjected to experimental treatments and the cells were trypsinized and harvested at specific time points. Luciferase activity was quantified using the Dual-Luciferase Assay System (Promega, Madison, WI) and TD-20/20 luminometer (Turner Biosystems, Sunnyvale, CA). The Firefly/Renilla activity ratio generated from the transcription factor-responsive reporter transfections were divided by the Firefly/Renilla activity ratio generated from the negative control transfections to obtain the relative luciferase units. Three independent transfections were carried out in triplicate for each of the conditions tested with each reporter assay.

### Electrophoretic Mobility Shift Assay (EMSA)

Assays were performed using the EMSA gel shift kit (Panomics, Fremont, CA) according to the manufacturer’s instructions. In brief, the biotin labeled EMSA probes for CREB and NF-kB binding assay was purchased from Panomics. The probe sequences were as follows:

- **CREB** 5’ AGAGATTTGCTGAGCTGAGCTAG 3’.
- **NF-kB** 5’ AGTTGAGGGGACTTTCCCAGGC 3’.

The DNA-protein binding reaction was performed in supplemented binding buffer containing 1 µl of probe, 5 µg of nuclear extracts, and 1 µl poly(dI-dC) at 15°C for 30 min. For competition studies, the nuclear extracts were incubated with 1- or 10-fold molar excess of unlabelled competitor oligonucleotides. All the DNA-protein complexes were analyzed on native 6% (w/v) polyacrylamide gels in 0.5 x TBE buffer (22.5 mM Tris-borate, 5 mM EDTA) at 120V for approximately 1 hour or until the dye front reached the bottom of the gel depending upon the fragment size. The gels were then transferred onto nylon membranes and fixed in an oven at 80°C for 1 hour and detected using streptavidin-HRP with a chemiluminescent substrate, and visualized by UVP Bio-imaging System. For supershift assays, a reaction mixture was prepared by adding 1–2 µl of appropriate antibody.
siRNA Mediated Gene Silencing in-vitro

Gene silencing was used to inhibit the expression of CREB in CATH.a neurons. The ON-TARGET plus Tm (Thermo Scientific) siRNA was used:

- Anti-CREB sequence - 5'-CCCTTCCCACTTTCCCTACA-3'.

The protocol was as per manufacturer's instructions. The siRNA was used at a final concentration of 0.1–0.5 μM. Transfection was done using siPORT amine (Ambion, Austin, TX) diluted in Opti-MEM I serum-free medium. The controls were treated with vehicle without the siRNA oligos. The culture were treated with vehicle without the siRNA oligos. The culture plates were assayed for target gene activity 24–48 hours after transfection by RT-PCR and Western blotting.

Co-immunoprecipitation (co-IP)

100 μg of CATH.a total protein lysate was tumbled with Roche Protein G beads (Roche, Indianapolis, IN) and pre-cleared for three hours. After centrifugation (20 seconds, 12,000 x g), the pre-cleared lysate was allowed to tumble with anti-CBP, anti-CREB or anti-p63 NF-κB antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hr prior to the addition of Protein G beads. The conjugated beads and lysate were tumbled overnight at 4°C. The beads were washed with two separate washing buffers (Buffer 1:50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Tween−20, 0.05% Na Deoxycholate; Buffer 2:50 mM Tris-HCl pH 7.5, 75 mM NaCl, 0.1% Tween-20) with protease inhibitor cocktail added on the day of experimentation. Protein was eluted from the beads using 50 μL of 2X 4% SDS sample buffer with β-mercaptoethanol (2.5% final concentration) added fresh and heated to 100°C prior to western blotting.

Statistical Analysis

The data are expressed as mean ± standard error of mean (SEM) and analyzed using one way ANOVA with Tukey's post-test analysis for comparison of intra as well as inter-group variance. Statistical significance was assumed when p<0.05.

Results

Phosphorylation of CREB at Ser133 by Ang II

To determine whether Ang II stimulation causes the phosphorylation of CREB at Ser 133 (a requirement for its activation), CATH.a cells were stimulated with Ang II (100 nM) for 1, 8, and 24 hours and the cell extracts were immunoblotted with an antibody that recognizes p-CREB at Ser133. These time points were chosen because we have shown previously that NF-κB was increased at these time points with a bi-phasic peak at 1 and 8 hours [7]. Ang II significantly increased p-CREB levels within 1 hour and sustained this increase for up to 24 hours (Fig 1A). Total CREB was also significantly increased with 8 and 24 hour Ang II stimulation (Fig 1A, white bars). We next asked if the increase in total p-CREB was concomitant with CREB activation (i.e. by CBP) at these time points. Immunoblot analysis of CBP indicated no significant increase in response to Ang II (Fig 1B).

Multiple Kinase Pathways Mediate Ang II-induced Phosphorylation of CREB

Phosphorylation of CREB can be modified through the activation of numerous kinase dependent pathways including CAMKs and p38 MAPK. We therefore examined if either of these pathways are responsible for Ang II-induced CREB phosphorylation (p-CREB). Thirty minutes prior to Ang II stimulation, pretreatment of CATH.a cells with SB203580 (10 μM), a p38MAPK inhibitor, significantly reduced p-CREB levels at 8 and 24 hour time points (Fig 2A). However, there appeared to be no inhibitory effect on p-CREB levels at 1 hour. 10 μM KN-62, a CAMK inhibitor, significantly blocked phosphorylation of CREB at 1 hour (Fig 2B) but did not prevent CREB phosphorylation at 8 hours (Fig 2C). Taken together, these results indicate that early activation of CREB likely occurs through the CAMK mediated pathway but with prolonged Ang II stimulation, the p38MAPK is the predominant pathway. PD98059 (10 μM), an ERK inhibitor, did not significantly alter p-CREB levels at 8 hrs of Ang II stimulation (Fig 2C). Given that these kinase pathways are all activated by Ang II stimulation, we next tested if blockade of AT1R with 1 μM losartan inhibited the Ang II-mediated increase in p-CREB. Losartan completely prevented the Ang II-induced CREB phosphorylation at all time points (Fig 2D).

The Effects of CREB knockdown on Downstream Activation of NF-κB, Elk-1, c-Fos and AT1R

We next assessed the contributions of CREB to the activation of NF-κB, Elk-1, c-Fos and upregulation of AT1R by silencing CREB with siRNA. To first confirm that the siRNA effectively decreased CREB, we assessed both mRNA and protein expression following siRNA transfection (Figure 3A). There was a significant decrease in CREB mRNA and protein detected in siRNA treated cells which persisted even following 1 and 8 hr Ang II stimulation. We then examined the effects of silencing CREB on p65 NF-κB expression following 1, 8, and 24 hr Ang II treatments (Fig 3B). Ang II-mediated increase in total NF-κB protein persisted despite CREB silencing at all time points of Ang II stimulation. In order to act as a transcription factor, NF-κB must translocate from the cytosol into the nucleus [25]. Interestingly, the absence of CREB led to a marked reduction in Ang II-mediated translocation of NF-κB in the nuclear fraction (Fig 3C), suggesting that although total NF-κB protein was unchanged, CREB may play a role in the activation and subsequent nuclear translocation of NF-κB.

Because Elk-1 and AP-1 have previously been reported to be involved in AT1R upregulation we next examined the effect(s) of silencing CREB on activation of these transcription factors and the subsequent upregulation of AT1R following Ang II stimulation [7,8]. Silencing CREB led to a decreased Ang II-mediated phosphorylation of both Elk-1 (Fig 3D) and cFos (Fig 3E). CREB gene silencing also prevented the Ang II-mediated increase in AT1R protein formation (Fig 3F).

Luciferase-reporter Assay as Indices of NF-κB and CREB Pathway Activity

Because Ang II increases CREB thereby stimulating NF-κB, we next investigated the interaction of CREB and NF-κB directly using CREB and NF-κB luciferase-reporter assays. As expected, we saw a substantial increase in NF-κB luciferase expression following Ang II which was abrogated by pretreatment with Losartan (Fig 4A). Cells that were transfected with CREB siRNA alone had decreased NF-κB luciferase activity compared to mock transfected non-stimulated cells, suggesting that CREB may drive basal NF-κB activation. CREB siRNA transfected cells that were stimulated with Ang II did not undergo any increase in NF-κB luciferase activity above CREB siRNA control. Further, this activity was significantly lower than mock transfected cells (Fig 4A). CREB luciferase expression was also increased following Ang II treatment in an AT1R-dependent manner, as this was
blocked by losartan pretreatment (Fig. 4B). As expected, silencing CREB with siRNA similarly caused a marked reduction in CREB luciferase activity following Ang II stimulation as compared to mock transfected control cells (Fig. 4B).

**Effect of Angiotensin II on the Interaction of CREB and NF-κB-DNA Binding**

In order to determine the transcriptional activity at the DNA level, we performed EMSA on CATH.a cells treated under different experimental conditions using consensus probes for both CREB and NF-κB. As a negative control, a sample containing no nuclear extract was used to confirm specificity (Fig. 5A, lane 1). Ang II stimulation of the CATH.a cells for 1 hour resulted in the formation of two prominent protein-DNA complexes (Fig. 5A, lane 2), which was prevented by 30 minute pretreatment with losartan or KN62 prior to Ang II stimulation (Fig. 5A, lane 3 and lane 5). Treating the cells with SB203580 prior to Ang II stimulation had no short term effect on the DNA binding at 1 hour, but DNA-protein binding was reduced at the 8 hour time point (Fig. 5A, lane 4 and lane 6). siRNA mediated CREB silencing resulted in a significant decrease in the DNA-protein binding (Fig. 5A, lane 8) as compared to the non-transfected control (Fig. 5A, lane 7).

We then examined the ability of CREB to influence the protein-DNA binding function of NF-κB using NF-κB-specific probes for EMSA reactions. Ang II caused the formation of a prominent DNA-protein complex (Fig. 5B, lane 1) which was prevented by pre-treatment with losartan (Fig. 5B, lane 2). Treatment of the cells with Ang II following CREB siRNA mediated gene silencing decreased DNA binding to NF-κB (Fig. 5B, lane 3) as compared to the non-transfected cells (Fig. 5B, lane 4). These data are consistent with our western blot analyses which showed a decrease in NF-κB nuclear translocation as a result of CREB inhibition. In this set of experiments, we again ran a negative control without nuclear extracts (Fig. 5B, lane 5). Taken together, the EMSA data corroborate the western blot analyses. The specificity of the NF-κB and CREB-DNA binding was confirmed by supershift assays using anti-p65 NF-κB and anti-CREB antibodies as well as performing competitive binding assays in the presence of excess cold probes (Fig. 5C and 5D).

**NF-κB and CREB Interaction is Facilitated by CBP**

We next asked if there was both a physical and functional interplay between CBP, CREB, and NF-κB. Co-immunoprecipitation (co-IP) analyses indicated there was no physical association between CREB and NF-κB (Fig. 6A, top and bottom panels). However there is physical binding between CBP and NF-κB (Fig. 6B) as well as CBP and CREB (Fig. 6C). To validate the co-IP experiments, we also repeated the experiments in the presence of blocking peptides against CBP or CREB (Figure S1). Indeed, in the presence of blocking peptide against either CBP or CREB, no positive bands were detected in either co-IP or total lysate. Our results therefore show that CBP acts as a facilitator to the binding of both NF-κB and CREB to their respective DNA domains independent of one another.

**Discussion**

In the present study we have demonstrated that Ang II stimulation leading to AT1R upregulation is mediated by an orchestrated sequential activation of the transcription factors...
CREB, NF-κB, Elk-1 and cFos. Our results are in agreement with previous reports that Ang II via AT1R indirectly activates CREB by phosphorylation of Ser133 [18]. A new finding in this study is that CREB acts coordinately with other transcription factors in regulating AT1R expression. We have further elucidated the key pathways resulting in CREB activation by Ang II, namely early activation by the CAMK pathway followed by sustained activation by the p38MAPK pathway. Finally, we have shown that CREB activation is critical for the nuclear translocation of the p65 component of NF-κB, which triggers the cascade of transcription factor activity leading to AT1R upregulation in response to Ang II.

Angiotensin II is the central member of the RAS. Overactivity of the RAS is a hallmark of several disease states characterized by sympathoexcitation such as heart failure and hypertension. Increased circulating Ang II and an upregulation of the AT1R are common manifestations in sympathoexcitatory states [2,3,26]. AT1R protein is increased in the sympathoexcitatory regions of the brain such as the RVLM. This occurs as a result of a positive feedback mechanism which can be blocked by the AT1R blocker losartan.

We have previously shown that AT1R upregulation is dependent on the increased activation of NF-κB [7] and AP-1

**Figure 2. p38MAPK and Ca++/CaMK pathways mediate CREB phosphorylation induced by Ang II.** Representative immunoblots showing the effect of (A) pretreatment with SB203580 (10 μM) followed by Ang II (100 nM) activation on p-CREB levels over a specified time course. (B) pretreatment with KN62 (10 μM) followed by Ang II (100 nM) at 1 hour on the phosphorylation of CREB. (C) CATH.a cells were preincubated for 30 minutes with PD98059 (25 μM), SB203580 (20 μM) and KN62 (10 μM) followed by Ang II (100 nM) for 8 hours. Cell lysates were immunoblotted for p-CREB. (D) Cells were preincubated with or without Losartan (1 μM) followed by Ang II (100 nM) for 8 hours. At the end of the specified time period, cell lysates were tested for p-CREB levels by western blot. *p<0.05 vs control, **p<0.05 vs 1 hr Ang II and †p<0.05 vs corresponding Ang II group. ‡p<0.05 vs 8 and 24 hr Ang II treatment. Values are expressed as mean ± SEM. n=3–4.

doi:10.1371/journal.pone.0078695.g002
[8,27] and simultaneous activation of Elk-1 [7]. Since NF-κB does not bind to the promoter site of cFos, Elk-1 may serve as the bridging protein thereby indirectly influencing cFos transcription [28]. Increasing evidence suggests that transcription factors work in a regulated network with one another to affect end point cell signaling [29,30,31]. The possible reasons for this co-dependent mechanism may be (a) to exert greater control over the end protein transcription or (b) redundant pathways regulating short term or long term effects of cell signaling initiators such as Ang II.

CREB is activated in neuronal cells and is involved in the transcription of genes which are involved in varied neurological processes ranging from behavioral adaptation [32] and learning [33] to targeting other transcription factors including c-Fos [13], which is intimately involved in AT1R gene transcription. Ang II activates several signaling pathways leading to the phosphorylation and subsequent activation of CREB at Ser-133. From our results, we have found that there are two distinct pathways which phosphorylate CREB; (a) early phosphorylation by Ca\(^{2+}\)/calmodulin-dependent protein kinase II which can be blocked by KN-62 and (b) a late phosphorylation process mediated by p38 MAPK that can be blocked by SB203580. Ang II has previously been known to activate p38 MAPK [34] most likely by the mitogen and

**Figure 3. CREB contributes to Ang II-mediated increases in AT\(_1\)R, NF-κB, active Elk-1, c-fos.** Knockdown of CREB by siRNA in CATH.a cells. (A) RT-PCR and Western blotting (lower panel) showing efficient suppression of CREB mRNA in CATH.a cells. (B) Inhibitory effect of CREB siRNA on Ang II-induced p65 NF-κB activation. siRNA transfected cells were stimulated with Ang II (100 nM) for 1 hour. p65 NF-κB levels were detected by western blotting. (C) Effect of CREB siRNA on p65 NF-κB nuclear translocation. Cells were transfected with CREB siRNA and subjected to Ang II activation over 1 hour period. Following nuclear/cytoplasmic fractionation, the lysates were immunoblotted for p-CREB and p65 NF-κB levels by western blotting in both nuclear and cytoplasmic fractions. (D) CATH.a cells were transfected with anti-CREB siRNA followed by Ang II stimulation for 8 hours. The cells were then probed with specific antibody against pElk-1 and (E) p-cFos. (F) Cells were either mock transfected with vehicle or anti-CREB siRNA and subsequently stimulated with Ang II (100 nM). Following the specified time course, the cells were probed for AT1R message (lower panel) and protein levels. Values are expressed as mean ± SEM. *p<0.05 vs control, #p<0.05 vs Ang II, †p<0.05 vs corresponding untreated nuclear fraction. n = 3–4 per treatment.

doi:10.1371/journal.pone.0078695.g003

**Figure 4. Ang II increases CREB and NF-κB activity in an AT1R and CREB-dependent manner.** CATH.a neurons were transfected with CREB and NF-κB reporter constructs, consisting of a mixture of CREB and NF-κB responsive luciferase constructs and a constitutively expressing Renilla construct. (A) NF-κB relative luciferase activity was quantified under several experimental conditions with Ang II treatment alone or pretreatment with losartan, anti-CREB siRNA or mock transfected cells. (B) CREB luciferase activity was measured under the similar experimental conditions. Values are expressed as mean ± SEM. *p<0.05. n = 3.

doi:10.1371/journal.pone.0078695.g004
stress activated protein kinase (MSK-1) [35]. Intracellular calcium and activation of the Ca\(^{2+}\)/CAMK pathway is also crucial for the Ang II mediated CREB activation [36]. Previous studies have shown that CAMK can phosphorylate CREB [13]. Our results clearly demonstrate that CAMK is involved in the early phosphorylation of CREB. Further evidence that CREB activation occurs through the Ang II-AT\(_1\)R axis is demonstrated by the fact that this process is blocked by losartan, a specific AT\(_1\)R blocker. The indirect interaction between CREB and NF-\(\kappa\)B may be a method of cross-talk between NF-\(\kappa\)B and CREB signaling pathways to compliment the integration of their signaling pathways together with their affinity for acting as a bridge to bring these molecules to the target promoter sites, since CREB and p65 NF-\(\kappa\)B interact with different regions of the coactivator. Co-operation between the two molecules exists as the CREB promoter contains binding sites for CREB in close proximity to p65 motifs [21]. NF-\(\kappa\)B has been shown to regulate the activity of other bZIP family members related to CREB (ATF-2, c-Jun, and c-Fos) [22,37]. The data presented here show that when CREB is silenced by siRNA, basal NF-\(\kappa\)B activity is decreased. NF-\(\kappa\)B and c-Fos (as part of AP-1) have been implicated as key molecules in the pathophysiology of heart failure and hypertension; despite being activated via different pathways, they share similar activation stimuli [38]. Both of these proteins have also been implicated in AT\(_1\)R upregulation in vitro [7].

In the present study, we have demonstrated that in neuronal cells CREB-NF-\(\kappa\)B interaction via CBP is necessary for downstream activation of other transcription factors including Elk-1 and AP-1 leading to the upregulation of the AT\(_1\)R as a result of Ang II activation. A summary of the pathway that our data support is outlined in Fig. 7.

**Limitations**

The goal of these experiments was to study the Ang II – AT\(_1\)R axis in neuronal cells. We accept that our cell model, the CATH.a neuron may not exactly mimic the cellular or molecular

---

**Figure 5. Ang II stimulates CREB and NF-\(\kappa\)B binding to DNA.** (A) CREB-DNA binding activity was determined under different treatment conditions using a CREB specific labeled probe. (Lane 1) No nuclear extract (negative control). (Lane 2) Ang II (100 nM). (Lane 3) Losartan (1 \(\mu\)M)+ Ang II (100 nM). (Lane 4) SB203580 (20 \(\mu\)M)+ Ang II (100 nM) at 1 hour. (Lane 5) KN62 (10 \(\mu\)M)+ Ang II (100 nM). (Lane 6) SB203580 (20 \(\mu\)M)+ Ang II (100 nM) at 8 hour. (Lane 7) Non-transfected cells (Ang II (100 nM)). (Lane 8) Transfected cells (CREB siRNA)+ Ang II (100 nM). (B) To study the synergistic actions of CREB and NF-\(\kappa\)B, we conducted EMSA reactions, using NF-\(\kappa\)B specific labeled probes under different conditions. (Lane 1) Ang II (100 nM). (Lane 2) Losartan (1 \(\mu\)M)+ Ang II (100 nM). (Lane 3) Transfected cells (CREB siRNA)+ Ang II (100 nM). (Lane 4) Ang II (100 nM). (Lane 5) Transfected cells (CREB siRNA)+ Ang II (100 nM). (Lane 6) Ang II (100 nM). (Lane 7) Transfected cells (CREB siRNA)+ Ang II (100 nM). (C) To confirm the specificity of the CREB-DNA binding bands we did competitive (Lane 1) and supershift assay (Lane 3) using anti CREB antibody, compared to normal CREB-DNA binding (Lane 2). (D) To confirm specificity of the NF-\(\kappa\)B-DNA bands, we similarly performed competitive assay (Lane 3) and supershift assay using anti-p65 antibody (Lane 4). Normal binding and negative control using no nuclear lysate are also included (Lane 2 and Lane 1, respectively). Fig. 5C is excluded from this article's CC-BY license. See the accompanying Expression of Concern for more information.

doi:10.1371/journal.pone.0078695.g005
Figure 6. CREB and p65 NF-κB do not physically associate and CBP binds to both CREB and p65 NF-κB. All representative blots are in the following order: Lanes 1–4: immunoprecipitated cell lysate, no ligand, Ang II, Los, Ang II+Los; Lanes 5–8: Total lysate, no ligand, Ang II, Los, Ang II+Los. (A). CREB (C) and p65 NF-κB do not associate. As shown in the first four co-IP lanes, there is no detectable signal but total p65 NF-κB was still detected. (B). CBP and p65 NF-κB physically associate as shown in the first four lanes. (C). CBP and CREB physically associate.

doi:10.1371/journal.pone.0078695.g006

Figure 7. A proposed model of Ang II-mediated AT1R upregulation. In response to an Ang II stimulus, NF-κB disengages from IκB and enters the nucleus to interact with the CBP and binds to the promoter region of Elk-1. In addition, CREB and CBP complex formation facilitates the interaction between p65 and the Elk-1 promoter. This sets up a downstream cascade mechanism involving the increased transcription of Elk-1 and the c-Fos component of AP-1 eventually leading to the upregulation of AT1 receptor.

doi:10.1371/journal.pone.0078695.g007
mechanisms or exhibit the identical phenotype of an adult neuron found in sympathetic regulatory regions of the brain. An alternative is to use primary cultures from neonatal or adult brains of in vivo models. But these models too have their inherent limitations. Neonatal cells may not react in a similar way to adult neuronal cells and hippocampal cell cultures may not reflect the molecular or signaling events occurring in neurons from the brain stem. The CATH.a cell line, despite its limitations, has been used for study of AT-R, R jnk [8], NF-kB [7], Elk-1 [39] and AP-1 [40].

In summary, we have for the first time demonstrated that CREB activation is necessary for AT1R protein synthesis in response to Ang II stimulation in neurons. Silencing the CREB gene using siRNA results in abrogation of the transcription factor activation of NF-kB, Elk-1 and cFos, resulting in decreased synthesis of AT1R protein. Furthermore we have shown that CBP acts as a transcriptional co-activator and integrates the binding of p65 and CREB to their respective promoter sites. Our results will further aid in understanding the mechanism of Ang II induced neural sympathoexcitotoxicity as seen in many disease states.

Supporting Information

Figure S1 Blocking peptides against CREB or CBP prevent all antibody binding. All representative blots are in the following order: No ligand IP, Ang II IP, no ligand total lysate, Ang II total lysate. (A) Pre-incubation with a blocking peptide for the rabbit anti-CREB antibody prevents any detection of either CBP/CREB dimeric species or CREB protein in total lysate. (B) Pre-incubation with the blocking peptide for the rabbit anti-CBP antibody prevents detection of either CREB/CBP dimeric species or CBP protein in total lysate. (C) Pre-incubation with a blocking peptide for the rabbit anti-CREB antibody prevents detection of any potential CREB/p65 NF-kB dimeric species and CREB total protein. (D) Pre-incubation with the blocking peptide against the rabbit anti-CBP antibody prevents the detection of both p65 NF-kB/CBP dimeric species and CBP total protein.

Author Contributions

Conceived and designed the experiments: IHZ KVH AKM. Performed the experiments: KVH AKM. Analyzed the data: KVH AKM. Wrote the paper: IHZ KVH AKM.

References

1. Steckelings U, Lehn B, Qadri F, Velmar A, Unger T (1992) Role of brain angiotensin in cardiovascular regulation. J Cardiovasc Pharmacol 19 Suppl 6: S72–79.
2. Zucker IH, Schultz HD, Patel KP, Wang W, Gao L (2009) Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. Am J Physiol Heart Circ Physiol 297: H1527–1536.
3. Gao L, Wang WZ, Wang W, Zucker IH (2008) Imbalance of angiotensin type I receptor and angiotensin II type 2 receptor in the rostral ventrolateral medulla: potential mechanism for sympathetic overactivity in heart failure. Hypertension 52: 708–714.
4. Li J, Brasier AR (1996) Angiotensinogen gene activation by angiotensin II is mediated by the rel A (nuclear factor-kappaB p65) transcription factor: one mechanism for the renin angiotensin system positive feedback loop in hepatocytes. Mol Endocrinol 10: 252–264.
5. Blume A, Herdegen T, Unger T (1999) Angiotensin peptides and inducible transcription factors. J Mol Med (Berl) 77: 339–357.
6. Gaborik Z, Jagadeesh G, Zhang M, Spat A, Catt KJ, et al. (2003) The role of a proline-rich domain-bZIP interaction. Mol Cell Biol 13: 3964–3974.
7. Mitra AK, Gao L, Zucker IH, Wang W (2008) Interaction between Neuronal angiotensin II type 1 receptor upregulation in heart failure: activation of activator protein 1 and Jun N-terminal kinase. Circ Res 99: 1004–1011.
8. Hu J, Behm DJ, Nerurkar S, Ebylve ME, Haimbach RE, et al. (2003) p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol Exp Ther 307: 932–938.
9. Yoshimoto T, Gochou N, Fukui N, Sugiyama T, Shichiri M, et al. (2003) Adrenomedullin inhibits angiotensin II-induced oxidative stress and gene expression in rat endothelial cells. Hypertension 38: 163–172.
10. Funakoshi Y, Ichiki T, Takeda K, Tokuno T, Iino N, et al. (2002) Critical role of cAMP-response element-binding protein for angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 277: 18710–18717.
11. Xu Q, Liu Y, Gorge M, Udelman R, Hofbrook NJ (1996) Acute hypertension activates mitogen-activated protein kinase in arterial wall. J Clin Invest 97: 508–514.
12. Sheng M, Thompson MA, Greenberg ME (1995) CREB: a Ca2+/calmodulin-regulated transcription factor phosphorylated by calmodulin-dependent kinases. Science 252: 1427–1430.
13. Xing J, Ginty DD, Greenberg ME (1996) Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273: 959–963.
14. Stakkestad O, Larsen AG, Kvisel AS, Elkvåg S, Orstrøm K, et al. (2011) Protein kinase A type I activates a CRE-element more efficiently than protein kinase A type II regardless of C subunit isoform. BMC Biochem 12: 7.
15. Yoshimoto T, Gochou N, Fukai N, Sugiyama T, Shichiri M, et al. (2005) FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAPK and MAPKAP kinase-2. EMBO J 15: 4629–4642.
16. Cardinaux JR, Notis JC, Zhang Q, Vo N, Craig JC, et al. (2000) Recruitment of CREB binding protein is sufficient for CREB-mediated gene activation. Mol Cell Biol 20: 1546–1552.
17. Cammarota M, Paratcha G, Bevilacqua LR, Levi de Stein M, Lopez M, et al. (1999) Cyclic AMP-responsive element binding protein in brain mitochondria. J Neurochem 72: 2272–2277.
18. Lee J, Kios CH, Simion DK, Aminova LR, Andreyev AV, et al. (2005) Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival. J Biol Chem 280: 40398–40401.
19. Spocter A, Kowijzman R, Lintermans B, Van Crogenbroek K, Vermeulen L, et al. (2010) Cooperation of NFkappaB and CREB to induce synergistic IL-6 expression in astrocytes. Cell Signal 22: 871–881.
20. Walker WH, Fucci L, Habener JF (1995) Expression of the gene encoding transcription factor cyclic adenosine 3',5'-monophosphate (cAMP) response element-binding protein (CREB) regulation by follicle-stimulating hormone-induced cAMP signaling in primary rat Sertoli cells. Endocrinology 136: 3534–3545.
21. Stein B, Cogswell PC, Baldwin AS Jr, (1993) Functional and physical associations between NF-kappa B and CREB family members: a Rel domain-bZIP interaction. Mol Cell Biol 13: 3964–3974.
22. Haack KK, Engler CW, Papoutsis E, Pipinos, II, Pacil KP, et al. (2012) Parallel changes in neuronal AT1R and GRK3 expression following exercise training in heart failure. Hypertension 60: 354–361.
23. Baruerle PA (1991) The inducible transcription activator NF-kappa B: regulation by glucocorticoid receptor physical interactions and antagonism. Mol Endocrinol 14: 1222–1234.
24. Li D, Gao L, Roy SK, Cornish KG, Zucker IH (2006) Neuronal angiotensin II type 1 receptor upregulation in heart failure: activation of activator protein 1 and Jun N-terminal kinase. Circ Res 99: 1004–1011.
25. Haack KK, Engler CW, Papoutsis E, Pipinos, II, Pacil KP, et al. (2012) Parallel changes in neuronal AT1R and GRK3 expression following exercise training in heart failure. Hypertension 60: 354–361.
26. Wang WZ, Gao L, Wang HJ, Zucker IH, Wang W (2008) Interaction between cardiac sympathetic afferent reflex and chemoreflex is mediated by the NTS AT1 receptors in heart failure. Am J Physiol Heart Circ Physiol 295: H1216–H1226.
27. Liu D, Gao L, Roy SK, Cornish KG, Zucker IH (2008) Role of oxidant stress on AT1 receptor expression in neurons of rabbits with heart failure and in cultured neurons. Circ Res 103: 186–193.
28. Schmeisser A, Saeedlou O, Emler T, Lorenz HM, Efsafi S, et al. (2008) ACF-2 inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. Biochem Biophys Res Commun 352: 532–540.
29. La Porta CA, Comolli R (1998) PKC-dependent modulation of βB alpha-NFkB pathway in low metastatic B16F1 murine melanoma cells and in highly metastatic B16 cells. Anticancer Res 18: 2591–2597.
30. Fan J, Zeller K, Chen YC, Watkins T, Barnes KC, et al. (2010) Time-dependent c-Myc transactomes mapped by Array-based nuclear run-on reveal transcriptional modules in human B cells. PLoS One 5: e9691.

31. Ganea D, Delgado M (2003) The neuropeptides VIP/PACAP and T cells: inhibitors or activators? Curr Pharm Des 9: 997–1004.

32. Ginty DD, Kornhauser JM, Thompson MA, Bading H, Mayo KE, et al. (1993) Regulation of CREB phosphorylation in the suprachiasmatic nucleus by light and a circadian clock. Science 260: 230–241.

33. Frank DA, Greenberg ME (1994) CREB, a mediator of long-term memory from mollusks to mammals. Cell 79: 5–8.

34. Ushio-Fukai M, Alexander RW, Akers M, Griendling KK (1998) p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem 273: 15022–15029.

35. Deak M, Clifton AD, Lucocq LM, Alessi DR (1998) Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J 17: 4426–4441.

36. Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, et al. (1998) Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem 273: 8090–8096.

37. Stein B, Baldwin AS Jr, Ballard DW, Greene WC, Angel P, et al. (1995) Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J 12: 3879–3891.

38. Karin M, Takahashi T, Kapahi P, Delhase M, Chen Y, et al. (2001) Oxidative stress and gene expression: the AP-1 and NF-kappaB connections. Biofactors 15: 87–89.

39. Stefano L, Al Sarraj J, Rosler OG, Vinson C, Thiel G (2006) Up-regulation of tyrosine hydroxylase gene transcription by tetradecanoylphorbol acetate is mediated by the transcription factors Elk-1 and Egr-1. J Neurochem 97: 92–104.

40. Swanson DJ, Zellmer E, Lewis FJ (1998) AP1 proteins mediate the cAMP response of the dopamine beta-hydroxylase gene. J Biol Chem 273: 24065–24074.

41. Coven E, Ni Y, Widnell KL, Chen J, Walker WH, et al. (1998) Cell type-specific regulation of CREB gene expression: mutational analysis of CREB promoter activity. J Neurochem 71: 1653–1674.

42. Thiel G, Al Sarraj J, Vinson C, Stefano L, Bach K (2005) Role of basic region leucine zipper transcription factors cyclic AMP response element binding protein (CREB), CREB2, activating transcription factor 2 and CAAT/enhancer binding protein alpha in cyclic AMP response element-mediated transcription. J Neurochem 92: 321–336.

43. Widnell KL, Chen JS, Iredale PA, Walker WH, Duman RS, et al. (1996) Transcriptional regulation of CREB (cyclic AMP response element-binding protein) expression in CATH.a cells. J Neurochem 66: 1770–1773.